...
首页> 外文期刊>Free Radical Biology and Medicine: The Official Journal of the Oxygen Society >Silybin combined with phosphatidylcholine and vitamin e in patients with nonalcoholic fatty liver disease: A randomized controlled trial
【24h】

Silybin combined with phosphatidylcholine and vitamin e in patients with nonalcoholic fatty liver disease: A randomized controlled trial

机译:水飞蓟宾联合磷脂酰胆碱和维生素E在非酒精性脂肪肝患者中的随机对照试验

获取原文
获取原文并翻译 | 示例
           

摘要

The only currently recommended treatment for nonalcoholic fatty liver disease (NAFLD) is lifestyle modification. Preliminary studies of silybin showed beneficial effects on liver function. Realsil (RA) comprises the silybin phytosome complex (silybin plus phosphatidylcholine) coformulated with vitamin E. We report on a multicenter, phase III, double-blind clinical trial to assess RA in patients with histologically documented NAFLD. Patients were randomized 1:1 to RA or placebo (P) orally twice daily for 12 months. Prespecified primary outcomes were improvement over time in clinical condition, normalization of liver enzyme plasma levels, and improvement of ultrasonographic liver steatosis, homeostatic model assessment (HOMA), and quality of life. Secondary outcomes were improvement in liver histologic score and/or decrease in NAFLD score without worsening of fibrosis and plasma changes in cytokines, ferritin, and liver fibrosis markers. We treated 179 patients with NAFLD; 36 were also HCV positive. Forty-one patients were prematurely withdrawn and 138 patients analyzed per protocol (69 per group). Baseline patient characteristics were generally well balanced between groups, except for steatosis, portal infiltration, and fibrosis. Adverse events (AEs) were generally transient and included diarrhea, dysgeusia, and pruritus; no serious AEs were recorded. Patients receiving RA but not P showed significant improvements in liver enzyme plasma levels, HOMA, and liver histology. Body mass index normalized in 15% of RA patients (2.1% with P). HCV-positive patients in the RA but not the P group showed improvements in fibrogenesis markers. This is the first study to systematically assess silybin in NAFLD patients. Treatment with RA but not P for 12 months was associated with improvement in liver enzymes, insulin resistance, and liver histology, without increases in body weight. These findings warrant further investigation.
机译:当前唯一推荐的非酒精性脂肪肝疾病(NAFLD)治疗方法是改变生活方式。水飞蓟宾的初步研究显示对肝功能有有益作用。 Realsil(RA)包含与维生素E共同配制的水飞蓟宾植物体复合物(水飞蓟宾加磷脂酰胆碱)。我们在一项多中心,III期,双盲临床试验中进行了报告,以评估组织学记录的NAFLD患者的RA。患者每天两次以1:1的比例随机分为RA或安慰剂(P),共12个月。预先确定的主要结局是随着时间推移临床状况的改善,肝酶血浆水平的正常化以及超声检查肝脂肪变性,稳态模型评估(HOMA)和生活质量的改善。次要结果是肝组织学评分改善和/或NAFLD评分降低而纤维化没有恶化,细胞因子,铁蛋白和肝纤维化标志物的血浆变化也没有恶化。我们治疗了179名NAFLD患者。 HCV阳性的也有36例。根据方案,有41例患者提前退出,并分析了138例患者(每组69例)。除脂肪变性,门静脉浸润和纤维化外,各组之间的基线患者特征通常很平衡。不良事件(AE)通常是短暂的,包括腹泻,消化不良和瘙痒。没有记录到严重的不良事件。接受RA但未接受P的患者在肝酶血浆水平,HOMA和肝组织学方面均表现出显着改善。体重指数在15%的RA患者中恢复正常(P为2.1%)。 RA组的HCV阳性患者而非P组的肝纤维化标志物有所改善。这是首次系统评估NAFLD患者中水飞蓟宾的研究。 RA而非P治疗12个月与肝酶,胰岛素抵抗和肝组织学改善有关,而体重没有增加。这些发现值得进一步调查。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号